---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-064315"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2024-03-11T23:59:59+00:00"
generated_at: "2026-06-04T23:52:09.577191+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Homology discloses lawsuit and demand letters challenging Q32 merger; provides supplemental proxy disclosures

## Summary
- Stockholder Kevin Welsh filed a putative class action on Feb 22, 2024 under Sections 14(a) and 20(a) alleging material omissions in the merger proxy statement.
- Twelve other purported stockholders sent demand letters with similar allegations regarding the proxy statement.
- Company denies all allegations and believes proxy complies with law, but voluntarily supplements disclosures to moot claims without admitting liability.
- Supplemental disclosures include additional details on TD Cowen's DCF analysis: perpetuity growth rate of (33)%, probability of success 15%-30%, discount rates 14%-17%.
- Separate 2022 securities class action (Pizzuto) remains pending; oral argument on motion to dismiss held March 4, 2024.

## SEC filing metadata
- accession: 0001193125-24-064315
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2024-03-11T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312524064315/0001193125-24-064315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312524064315/d806643d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-064315
- JSON: https://secwatch.observer/filing/0001193125-24-064315.json
- Plain text: https://secwatch.observer/filing/0001193125-24-064315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.